BCR and acute lymphoblastic leukemia: In our study, we report the anti-leukemic effects of CEL_Amide, a novel highly specific small molecule inhibitor of LIMK1/2, in BCR::ABL+ ALL cells and in a BCR::ABL+ mouse model, which, to our knowledge, is the first report of preclinical activity of a LIMKi in BCR::ABL+ B-ALL.